The combined company is supported by $50 million in capital from Ligand and a group of outside investors. The team plans to launch the FDA-approved topical molluscum treatment Zelsuvmi this summer. More: Ligand's Pelthos unit joins forces with Channel Therapeutics
read moreThe tortoise (Eli Lilly) has caught the hare (Novo Nordisk), according to a report from BMO Capital Markets, which cites the superior commercial and clinical portfolios of the Indianapolis company compared to those of its Danish rival. More: Eli Lilly
read moreGSK has secured the first regulatory approval for Blenrep since the antibody-drug conjugate’s global market withdrawal in 2022. More: GSK kicks off Blenrep's market return with first myeloma combo nod in UK Source: fierce
read moreIn an interview with BMO Capital Markets, a prominent former FDA official has sounded the alarm about the potential for mass layoffs at the agency to disrupt the agency’s drug review process. The threat, which would be particularly pronounced for
read morePharma advertisers have kicked off 2025 with a bang, with the top 10 spenders throwing almost 30% more money behind their TV commercials in the first quarter compared to the same period a year ago. More: TV drug ad spending
read more
More than 37 million adults in the US are affected by migraine More: FDA approves Click’s digital therapeutic for episodic migraine Source: News
read more© 1994 - 2025 B.M. Pharmaceuticals